This study examines growth alterations in liver foci and tumor developmen t as a basis for the different susceptibility in hepatocarcinogenesi s found among different strains of mice. Male C57, B6C3F1, and C3H mice treated with a single dose (1 mg/kg) of N,N-diethylnitrosamine (DEN) at 15 days of age and followed up to 12 months displayed a strain-dependen t (C3H > B6C3F1 > C57) increase in incidence, number, volume fraction, and size of foci and macroscopi c lesions (masses). DEN-treated mice exhibited a time-dependent increase in foci size but not in foci number. Phenobarbital (PB) treatment (500 ppm) in the drinking water starting 2 weeks after DEN-initiation did not affect the incidence or number of masses and foci. In all 3 strains, the bromodeoxyuridin e labeling index in foci correlated with foci growth, supporting the major role of cell proliferation in foci growth. Measurements of apoptosis by morphologica l criteria with H&E staining suggest that intrafocal apoptosis may be a late event preventing foci growth and possibly also promoting focal cell selection, whereas extrafocal apoptosis may facilitate clonal growth by removing adjacent normal cells. The onset of conversion of foci to masses also correlated with strain susceptibility to hepatocarcinogenesis .
INTRODUCTION
The B6C3F1 mouse is used extensively in many carcinogenicity bioassays including those conducted by the National Toxicology Program (NTP) . Approximately 56% of all chemicals tested in the NTP bioassay have been identi ed as mouse carcinogens, and 57% of these were found to induce mouse liver tumors (7, 8) . Chemicals that have been identi ed as mouse hepatocarcinogens affect the decision-making process in chemical cancer risk assessment. The relevance of mouse hepatocarcinogenicity to human risk is still an unresolved issue in the scienti c and regulatory community. A main reason for this controversy stems from the high incidence of spontaneous liver tumors observed in the B6C3F1 mice and the high variability in spontaneous and chemically induced liver tumors found among different strains of mice (12) . A resolution of this important issue requires an understanding of the underlying mechanisms in mouse liver carcinogenesis.
In this study, we tested the hypothesis that alterations in proliferation and apoptosis in liver foci and tumor development are a basis for the different susceptibility in liver tumor development among various mouse strains. Portions of this study were presented (entitled "Quantitation of Cancer Processes") at the 2001 Society of Toxicologic Pathology meeting-many aspects of this study design concepts and data assessments are examples of approaches that can be utilized to provide quantitative data for studying cancer processes.
The B6C3F1 mouse is a hybrid cross between the male C3H/HeJ and female C57BL/6J mouse strains. The susceptibility to liver tumor development among these mice is very different. The C3H strain and the B6C3F1 hybrid display a relatively high sensitivity to spontaneously and chemically induced liver tumors, whereas the C57BL/6J is comparatively resistant to liver tumor development (4, 12) . This strainspeci c liver tumor susceptibility is likely to be genetically controlled by intrinsic genetic differences in the hepatocytes (17) , and several lines of evidence indicates that this genetic susceptibility is dependent on multiple genes, termed Hcs (hepatocarcinogen sensitivity) genes (5) . Although the biological function of these genes has not been fully unveiled, segregation and genetic linkage analysis suggest that at least 6 to 7 different Hcs genes may be involved in the high liver tumor susceptibility observed in the C3H/HeJ mouse (1, 5, 6, 20) . In addition, linkage studies in D2 mice suggest that cancer resistance genes exist and that the interactions between sensitivity and resistance genes dictate susceptibility to liver tumor development (16) . Several studies have examined if differences in mouse susceptibility to hepatocarcinogens is at the level of initiation, promotion, or progression stages of liver tumor development (5, 12, 14, 15, 18, 28, 38) . Collectively, studies suggest that mouse liver tumor susceptibility is, at least in part, related to differences in growth regulation of initiated hepatocytes.
Cell proliferation and cell death (apoptosis) are equally important in cell growth and critical throughout multistage carcinogenesis (9, 32) . Several lines of evidence indicate that a net increase in the number of initiated cells and growth of foci and tumors is directly dependent on how chemicals affect the rates of cell proliferation and cell death. A variety of agents, including liver carcinogens and tumor promoters, have been shown to affect hepatocyte growth processes (2, 13, 22, 35, 36) . Often, both cell proliferation and apoptosis are elevated in hepatic foci, suggesting that apoptosis may suppress foci growth by counteracting cell proliferation (31) . Apoptotic bodies have also been detected in the area of compressed cells that surrounds foci and tumors (10) . This suggests that foci growth may not only be dependent on the net balance between cell proliferation and apoptosis within foci and tumors, but also dependent on the removal of the neighboring normal cell population.
Evaluating growth and development of foci and tumors at multiple time points in different strains of mice in a single study will lead to insights into the mechanisms involved in mouse strain susceptibility and, furthermore, aid in resolving the controversial issue about the variability in spontaneous and chemically induced tumors found among different strains of mice. We hypothesize that differences among mouse strains in foci and tumor growth rate are likely to play an important role in mouse liver tumor susceptibility through strain-dependent regulation of cell proliferation and apoptosis. The present study determined the development and growth characteristics of preneoplastic liver foci and tumors in C57, B6C3F1, and C3H male mice initiated at 15 days of age with a low dose of DEN. Additionally, groups of DEN-initiated mice were exposed to PB starting at 4 weeks of age to investigate strain differences in foci and tumor growth responses to the effects of PB. To determine the relative roles of cell proliferation and cell death in mouse hepatocarcinogenesis and mouse liver tumor susceptibility, nonfocal and focal cell proliferation and apoptosis were assessed at multiple time points.
METHODS Chemicals: N,N-diethylnitrosamine (0.95 g/ml), phenobarbital sodium salt and bromodeoxyuridine (BrdU) were all obtained from Sigma Chemical Co. (St. Louis, MO). DEN was diluted in Dulbecco's phosphate-buffered saline liquid (D-PBS, 1x) from GIBCO-BRL (Gaithersburg, MD) and was aliquoted and stored in a freezer at 20 C. The phenobarbital salt was dissolved in lter-puri ed tap water every second week. The BrdU salt was dissolved in D-PBS in the morning prior to pump implantation.
Animals and Treatment:
All animals were maintained in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals (1985) . C57BL/6NCrlBR (C57) and C3H/HeNCrlBR (C3H) mice free of common murine pathogens (viral antibody-free) were obtained from Charles River Breeding Laboratories (Raleigh, NC) and acclimated at upon arrival for 10 to 12 days. Humidity was maintained at 30 to 70% and temperature 20 to 25 C. The room air was HEPA-ltered. Animal rooms were maintained on a 12-hour light-dark cycle, with the light period extending from 7 am to 7 pm. The animals were fed NIH-07 open formula pellet food (Zeigler Brothers, Gardens, PA) and deionized tap water ad libitum. Nulliparous females, 8 to 10 weeks old, were paired 1:1, and mating was con rmed by the presence of a vaginal plug. B6C3F1 offspring were obtained by breeding male C3H and female C57 mice. At 15 days of age, male C57, B6C3F1 and C3H mice were injected ip with 1 mg DEN/kg body weight or PBS alone. The animals were randomly allocated to the different 14-day, 21-day, 5-month, and 9-month treatment groups at weaning when they were 21 to 27 days old. In addition, surplus animals were randomly distributed to the 12-month groups (6-20 animals/group). Seven days after weaning, at the age of 28 to 34 days, one half of the groups of noninitiated and DEN-initiated mice started on drinking water containing 500 ppm PB.
To investigate early mitogenic effects of PB, groups of animals (7 animals/group) were sacri ced at 14 days of age prior to the scheduled start of PB treatment and at 21 days of age when the mice had been treated with PB for 1 week. To study strain-dependent effects on the development of DEN-initiated preneoplastic foci and macroscopic liver lesions (masses), noninitiated control mice and DEN-initiated mice were sacri ced at 5, 9, and 12 months. The effects of PB on DENinitiated lesions were studied by including PB-treated groups of noninitiated and DEN-initiated animals that were sacriced at 5 and 9 months. In C57 and B6C3F1 mice, the initial numbers of animals per group were 7, 7, 9, and 15 for the 14-day, 21-day, 5-month, and 9-month time points, respectively. In the C3H mice, the same number of animals were used per group except for the PB group at 5 months and the control and DEN PB groups at 9 months. In these 3 groups, 8, 14, and 14 animals were included, respectively.
Necropsy: At necropsy, mice were weighed, anesthetized, examined for grossly visible lesions, and exsanguinated. Livers were excised, weighed, and examined for macroscopic lesions. The number of macroscopic hepatic masses 1 mm was determined as well as the size of the masses by taking the average of the largest and smallest length of the mass. Representative standard liver samples (3-4-mm slices) for foci quantitation were taken from the left, right median and anterior lobes, xed in 10% neutral buffered formalin for 48 hours and then transferred to 70% ethanol. Within a week, the liver samples were embedded in paraf n and subsequently sectioned at 5 l m and stained for hematoxylin and eosin (H&E).
Quantitation of Hepatic Preneoplastic Lesions:
H&Estained slides of liver sections were examined microscopically for visible lesions with the experimenter blind to the treatment group. The lesions were mapped and identied as foci, adenomas or carcinomas. All preneoplastic foci 10 cells in size were scored and classi ed according to histopathologica l phenotype using standard criteria (21, 37) . The total area of the sections from the left, right median, and anterior lobes as well as the transection areas of all lesions were determined on H&E stained slides with an Image-1 processing system (Universal Imaging Corp, West Chester, PA). The areas of adenomas and carcinomas were withdrawn for the total section areas for foci stereologic calculations. The number of preneoplastic foci per cm 3 , the volume fraction of liver occupied by foci and the mean foci volume were determined by stereology using a focal pro le cutoff with diameter 65l m (24, 28) .
Calculation of Conversion Factors:
The calculation of conversion of foci to tumors was evaluated by dividing the mean number of foci/liver at 5 months by the mean number of observable macroscopic lesions/liver at 9 and 12 months. The number of foci/liver was obtained by multiplying the number of foci/cm 3 with the liver weight, assuming a liver density of 1 g/ml. To determine the variation in the calculated mean ratios, the lower SEM of foci/liver was divided with the lower SEM of masses/liver, and the upper SEM of foci/liver was divided with upper SEM of masses/liver. BrdU Administration and Labeling Index: BrdU was administered by surgically implanting miniosmotic pumps (Model 2001, pumping rate 1.0 ml/hr; ALZET Corp, Palo Alto, CA) containing 30 mg BrdU/ml 3.5 days prior to necropsy. For the 21-day time point, however, pumps were implanted 7 days prior to necropsy to ensure a complete labeling of the rst week of PB exposure. Serial liver sections next to the H&E sections were immunohistologically stained for BrdU, and labeling index was determined by light microscopy with the investigator blind to animal treatment, as described elsewhere (11) . Nonfocal labeling index was determined for the 14-day, 21-day, and 5-month postinitiation time points by counting random elds of the left lobe and dividing the number of labeled hepatocyte nuclei by the total number of nuclei counted and multiplying by 100. The minimal total number of nonfocal hepatocyte nuclei counted was 1,000 for the 14-and 21-day time points and 2,000 for the 5-month time point. Focal labeling index was determined for the 5-and 9-month time points on foci initially located on H&E slides and subsequently identi ed on BrdU slides. Focal labeling index was de ned as percentage of the labeled hepatocyte nuclei in the focus divided by the total number of focal hepatocyte nuclei. The number of animals/group receiving pumps were 7, 7, 4-5, and 10 for the 14-day, 21-day, 5-month, and 9-month time points, respectively.
Apoptosis Measurement: Apoptosis bodies and early apoptotic cells with condensed chromatin were identi ed on H&E-stained slides as previously described (10) . Nonfocal apoptotic index was de ned as the percentage of apoptotic bodies and early apoptotic cells among total counted number of hepatocyte nuclei. A minimum of 2,000 nonfocal hepatocyte nuclei were counted. Focal apoptotic index was determined by dividing the counted number of focal apoptotic bodies and early apoptotic cells with the estimated number of focal hepatocyte nuclei and multiplying by 100. The estimation of the number of focal hepatocyte nuclei was accomplished by determining the number of nuclei/mm 2 and multiplying this number with foci area. Because the cell density varies among different foci phenotypes, the speci c number of nuclei/mm 2 was determined for different foci phenotypes. Extrafoci apoptotic index was determined for each individual focus by dividing the number of focal apoptotic bodies and early apoptotic cells observed adjacent to foci with the number of hepatocyte nuclei in the extrafocal area and multiplying by 100. Extrafocal apoptotic bodies and cells were de ned as those located within 5 nuclei layers from the foci. The number of extrafoci hepatocyte nuclei was calculated by geometric methods using the estimated number of focal nuclei for each individual focus.
Statistical Analysis: Incidence of foci and macroscopic lesions were analyzed by Fisher's exact test. All other experimental data were tested by group for normality with the Shapiro-Wilk test and homogeneity with the O'Brien test. When appropriate, data were log-transformed prior to statistical analysis to meet normality and/or homogeneity assumptions. Labeling index and apoptotic index data were arcsine transformed. If normality/homogeneity assumptions were met by transformation, the data were analyzed by 1-way AVONA. When signi cant, Dunnett's test was used to determine which treatment groups were different from the control group. In some cases, the Tukey HSD test was used for multiple comparisons among all groups. If normality/homogeneity assumptions could not be met, nonparametric methods were used by employing Kruskal-Wallis and Dunn's tests. The signi cance level for all analyses was p < 0.05.
Results
Clinical Observation, Survival, Body Weight and Liver Weight: The general appearance of the animals, survival, food, and water consumption were not affected by the various treatments. A signi cant decrease in body weight was observed in PB-and DEN-treated C57 mice at 5 months; however, relative to the controls, no sustained alteration in body weight was observed in any group of mice.
PB induced similar liver enlargement in all 3 strains. A sustained increase in liver weight was observed at 21 days, 5 months, and 9 months in PB-and DEN PB-treated mice in all 3 strains as compared to the corresponding controls. Centrilobular hypertrophy was evident in all these groups, contributing to the enhanced liver weight. No strain differences in liver weight were observed, suggesting that the control of liver weight is equally affected by PB treatment among the strains. Liver weight was increased at 12 months in DEN-initiated animals of all 3 strains as well as at 9 months in C3H mice. The increased tumor burden observed in these groups as well as in the DEN + PB groups was clearly a contributing factor to the increased liver weight in these groups.
Incidence of Macroscopic Liver Lesions:
Macroscopic hepatic lesions (masses; adenomas and carcinomas) were observed in occasional control and PB-only treated B6C3F1 mice and C3H mice at 9 months, and in control mice of all 3 strains at 12 months (Table 1 ). In DEN-initiated only mice, the incidence was minimally increased at 5 months in all 3 strains, although only signi cantly in the B6C3F1 strain. At 9 months, the incidence of masses observed at necropsy was signi cantly increased in DEN-initiated mice in all 3 strains. At 12 months, the incidence was signi cantly increased in DEN-initiated C57 mice and B6C3F1 mice relative to the controls. Although not signi cantly different from the controls, likely due to the low number of animals, the incidence of hepatic lesions was also increased at 12 months in DEN-initiated C3H mice. In DEN PB-treated mice, the lesion incidence was weakly increased at 5 months in B6C3F1 mice and signi cantly increased in the C3H mice. Similarly to DEN initiated mice, the incidence was signi cantly increased in DEN PB-treated mice as compared to control mice in all three strains at 9 months. Both DEN and DEN PB treated mice exhibited strain-dependent increased lesion incidence at 9 and 12 months (C3H > B6C3F1 > C57).
Multiplicity of Macroscopic Liver Lesions:
The number of masses per mass-bearing animal in DEN-treated mice was relatively low and was approximately the same in all three strains at 5 months (Table 1) . At 9 months, sporadic masses were observed in control and PB-treated B6C3F1 and C3H mice. At this time point, DEN-and DEN PB-treated mice exhibited a strain-dependent increase in lesion multiplicity (C3H > B6C3F1 > C57). Within each strain, the multiplicity appeared to be similar at 9 months in the DEN and DEN PB groups, suggesting that PB did not affect the number of observable DEN-initiated masses. An increase in masses per mass-bearing animal was observed between 9 and 12 months in DEN-treated C57 and B6C3F1 mice. In DEN-treated C3H mice, the multiplicity went down from 21.6 to 13.0 masses per mass-bearing animal. This was probably a result of the substantial increase in mass size between 9 and 12 months that made it dif cult to distinguish individual masses. Overall, C3H > B6C3F1 > C57 in the incidence and multiplicity of hepatic masses. Liver Foci Incidence: The incidence of animals having foci transactions in liver sections taken from representative liver samples exhibited the same pattern as that observed for macroscopic lesions ( Table 2 ). Foci were observed in 1 control C3H mice at 9 months, and in control C57 and C3H mice at 12 months (Table 2) . DEN-and DEN PB-treated mice displayed a slight increase in foci incidence at 5 months in all 3 strains that was signi cant in only DEN-initiated C3H mice. The increase in DEN-and DEN PB-treated mice was more evident at 9 months, where the liver foci incidences were increased in all 3 strains. Similar to the data on tumor incidence and multiplicity, 9-and 12-month DEN and DEN PB groups displayed the highest foci incidence in C3H mice followed by B6C3F1 and C57 mice.
Number of Foci/cm 3 : DEN-initiated animals exhibited an increased number of foci/cm 3 in all 3 strains at all time points relative to the controls. The increase was statistically signicant in DEN-treated animals at 9 and 12 months in B6C3F1 mice and at 5, 9, and 12 months in the C3H mice ( Table 2 ). DEN PB-treated B6C3F1 and C3H mice also showed a signi cant increase in foci density relative to the controls at 9 months. This increase did not differ signi cantly from the DEN groups at 9 months, indicating that PB did not in uence the number of foci induced by DEN in these 2 strains. In C57 mice, a weak but nonsigni cant increase in foci/cm 3 was observed in both the DEN-and DEN PB-treated mice.
Volume Fraction of Liver Occupied by Foci: DEN caused an increase in the volume fraction of liver occupied by foci at 12 months in C57 mice, at 9 and 12 in B6C3F1 mice, and at 5, 9, and 12 months in C3H mice. The volume fraction was also increase in DEN PB-treated C3H mice at 5 and 9 months relative to the controls. The focal volume fraction was strikingly similar in DEN and DEN PB-treated C3H mice at 5 and 9 months, strongly suggesting that PB was not affecting the DEN-induced volume fraction in C3H mice. In contrast, the volume fraction was signi cantly less in DEN PB-treated C57 and B6C3F1 mice as compared to the respective DEN-treated mice. PB appears to suppress the volume fraction of DEN-induced foci but not alter the number of foci/cm 3 in B6C3F1 and C57 mice.
Foci and Mass Sizes: As shown in Figure 1a , DEN-induced foci displayed a strain-dependent difference in foci growth at 5, 9, and 12 months (C3H > B6C3F1 > C57). At 12 months, mean foci volume in C3H mice was approximately 2 and 5 times larger as compared with B6C3F1 and C57 mice, respectively. The data on the number of foci/cm 3 as well as foci volume fraction observed in DEN-and DEN PB-treated B6C3F1 and C3H mice suggests that PB affected the size of DEN-induced foci differently in B6C3F1 and C3H mice. Indeed, PB was found to substantially suppress the growth of DEN-induced foci in B6C3F1 mice while no such effect was observed in C3H mice (Figure 1b) . In fact, the mean foci volume did not increase signi cantly between 5 and 9 months in DEN PB-treated B6C3F1 mice. The limited number of foci observed in C57 mice did not display any signi cant effects on DEN-induced foci that could be related to PB treatment.
DEN-induced macroscopic lesions also exhibited straindependent growth rates (C3H B6C3F1 > C57). The mean mass size at 12 months was about the same in C3H and B6C3F1 mice and approximately 2 times larger than the mass size in C57 mice (Figure 2a ). Although PB did not completely repress the growth of macroscopic lesions in B6C3F1 as it did foci growth, the outgrowth of masses was re- duced in DEN PB-treated B6C3F1 mice as compared with DEN-treated B6C3F1 mice (Figure 2b ). Relative to B6C3F1, alteration in mass size between DEN-and DEN-PB-treated C3H mice was less affected.
Foci to Tumor Conversion Ratios: When the number of foci/liver at 5 months was compared with the number of masses/liver at 9 months, a strain-dependent difference was observed. The conversion ratio between 5 and 9 months was found to be 24.4 (range 15.7-28.1), 6.9 (range 3.7-9.2) and 2.6 (range 2.2-3.1) in DEN-treated C57, B6C3F1, and C3H mice, respectively. Interestingly, PB did not appear to markedly affect the strain-dependent conversion of DEN-induced foci to tumors. In DEN PB-treated mice, the conversion ratios between 5 and 9 months were 15.3 (range 7.0-18.6), 9.2 (range 5.4-11.7) and 2.8 (range 1.5-3.8) in C57, B6C3F1, and C3H mice, respectively. The foci-tomass conversion between 5 and 12 months was not different between the strains, however. In DEN-treated mice, the conversion ratios between 5 and 12 months were 4.1 (range 2.5-4.8), 3.2 (range 1.6-4.4), and 3.8 (range 3.1-4.5) in C57, B6C3F1, and C3H mice, respectively. Taken together, this suggests that the overall conversion of foci to tumor is the same among the strains but that the onset of conversion is strain-dependent, with foci to tumor conversion occurring as an earlier event in C3H mice relative to B6C3F1 and C57 mice.
Nonfocal and Focal Labeling Index: Nonfocal labeling index was measured at the 14-day, 21-day, and 5-month time points prior to occurrence of substantial liver tumor burden. As expected, the nonfocal labeling index decreased over time, re ecting the age-dependent decrease in liver growth. The nonfocal labeling index was not affected by DEN, indicative of the single administration of a noncytotoxic DEN dose. At the 21-day time point, (i.e., after 1 week of PB treatment), the nonfocal labeling index was signi cantly increased in the PB and DEN + PB groups in all 3 strains (2.4to 3.7-fold increase). The PB-induced increase in nonfocal labeling index was most pronounced in the C57 strain, which was signicantly ( p < 0.05) higher compared with the other 2 strains.
Focal labeling index was analyzed at 5 and 9 months. The focal labeling index was markedly greater in all strains compared to nonfocal LI (nonfocal LI range, LI 0.05-0.29%; focal LI range, LI 4.3-18.3%). The limited number of foci scored and the large LI variation within foci did not permit an adequate database for statistical comparisons among the mouse strains. However, the data suggest a lower focal LI in C57 mice (LI range 4.3-13.2%) as compared with B6C3F1 (LI range 9.4-18.0%) and C3H (LI range 14.5-18.3%). When the 5-and 9-month LI of all individual foci were grouped together, the LI were found to be signi cantly lower in C57 mice as compared to the other 2 strains. PB exhibited some effects on focal LI in B6C3F1 mice. A lower mean LI in DEN PB-treated B6C3F1 mice from DEN-treated B6C3F1 mice was observed when the group means of individual animals were compared. At 5 and 9 months, LI in B6C3F1 DEN treated mice was 15.1 10.6 and 18.0 4.8, respectively; LI in DEN PB treated B6C3F1 mice was 9.4 9.4 (5 months) and 9.5 2.7 (9 months). When the labeling indices of individual foci from both time points were grouped together, a signi cant difference was detected between DEN-and DEN PB-treated B6C3F1 mice. In C3H mice, no signi cant difference was observed in focal labeling index between DENand DEN PB-treated mice at 5 and 9 months. The PBinduced decrease in focal labeling index observed in B6C3F1 mice and the lack of such an effect in C3H mice correlated with PB-induced effects on foci and mass growth in these two strains (Figures 1 and 2) .
Apoptotic Index: The apoptotic index was measured in H&E-stained slides at 5 and 9 months. No intrafocal or extrafocal apoptotic bodies were found in the limited number of foci that were available in C57 mice. Collectively, approximately 10,000 intrafocal nuclei and 9,000 extrafocal nuclei from 23 foci were assessed in C57 foci, indicating a low apoptotic activity ( 0.01%).
In B6C3F1 mice, apoptotic bodies were not observed intrafocally in 12 foci (5,023 cells) at 5 months, again indicating a low apoptotic index. At 5 months, only 1 extrafocal apoptotic body was observed in 7 foci (2,872 cells) in DEN-initiated B6C3F1. Intrafocal apoptosis was observed at 9 months in DEN (21 foci; 47,965 cells) and DEN PB (10 foci; 9,117 cells)-treated B6C3F1 mice; the apoptotic index was not signi cantly different between the groups. Although not statistically signi cant, the extrafocal index at 9 months suggests that apoptosis occurred more frequently outside foci in DEN-treated B6C3F1 mice than in DEN PB-treated B6C3F1 mice, perhaps contributing to their increased growth.
In C3H mice, no intrafocal (9 foci; 3,002 cells) or extrafocal (9 foci; 3,408 cells) apoptosis was observed at 5 months. Intrafocal and extrafocal apoptosis was, however, frequently observed at 9 months in C3H mice. Although not statistically con rmed due to the low number of apoptotic bodies observed, the mean intrafocal apoptotic index was higher in DEN PB-treated mice (43 foci; 85,600 cells; AI 0.30%) as compared with DEN-treated C3H mice (56 foci; 103,473 cells; AI 0.08%), whereas the extrafocal apoptotic index was higher in the DEN group relative to the DEN PB-treated group (0.26% and 0.11%, respectively). In the DEN PB group, apoptotic bodies were mainly observed in foci of amphophilic or mixed phenotype. In fact, approximately 80% of all intrafocal apoptotic bodies detected in the DEN PB group were found in these foci, which substantially contributed to the high apopototic index observed in this group.
The increased extrafocal apoptotic index observed at 9 months in DEN-treated B6C3F1 mice and in DEN-and DEN PB-treated C3H mice was limited to the adjacent area surrounding the foci. The nonfocal associated apoptotic index in these mice was found to be less or equal to 0.01%, suggesting an increase in extrafocal apoptosis over that of nonfocal associated apoptosis of approximately 10 times.
DISCUSSION
In the present study, the hepatic carcinogenic effects of DEN and PB were studied in relatively resistant and responsive strains of mice at multiple time points. The results show that the growth and development of preneoplastic foci and tumors in male mice induced by a single injection of a low, noncytotoxoic dose of DEN at 15 days of age was mouse strain-dependent (C3H > B6C3F1 > C57). The number of foci was also different among the strains at all time points, correlating to the strain-dependent hepatocarcinogenic susceptibility. However, within each strain the number did not change signi cantly over time. This suggests that differences in strain susceptibility may also occur early in the liver carcinogenic process, perhaps involving not only straindependent growth differences but also differences in early postinitiation events such as removal of initiated cells through apoptosis (5) .
PB treatment starting 2 weeks after DEN initiation did not affect the incidence or the number of masses and foci in either strain. PB did signi cantly counteract the growth of DEN-initiated preneoplastic foci and macroscopic lesions in the B6C3F1 hybrid mice but not in C3H mice. With regard to the effect of PB on foci and tumor growth, C57 mice appeared to act like B6C3F1 mice, but the low number of foci and masses in C57 mice did not allow de nitive conclusions within this mouse strain. The negative in uence of PB on foci and masses in the more resistant liver tumor prone mice appears to be related to growth alterations since PB affected neither the incidence nor the number of foci and masses. The suppressing properties of PB on foci and mass growth con rm previous observations using carcinogen-treated infant male B6C3F1 mice followed by long-term PB treatment starting at weaning (3, 25) . The present study further demonstrates a strain speci c hepatocarcinogenic inhibitory response to PB (23) .
As expected, PB induced an early increase in nonfocal labeling index and a sustained hypertrophy. Interestingly, the PB-induced increase in labeling index was signi cantly higher in the liver tumor-resistant C57 mice relative to the susceptible C3H and B6C3F1 mice. This nding support previous studies (19) and suggest that C57 mice are more responsive to the early nonfocal PB-induced proliferation. Despite the higher nonfocal labeling index in C57 mice, the increase in liver weight in the PB and DEN PB groups was not different among the strains. This may suggest less pronounced hypertrophy in the C57 mice as compared with the other two strains as previously reported (19) . Alternatively, PB-induced cell proliferation may be counteracted by compensatory apoptosis to prevent excessive cell production (32) . This hypothesis clearly needs further investigation because increased apoptosis following carcinogens treatment may play an important role in removing initiated cells (31) and may therefore contribute to the lower tumor incidence observed in C57 mice.
Clonal expansion of initiated cells is the hallmark of promotion in multistage carcinogenesis (26) . Measurement of cell proliferation is therefore crucial in elucidating the potential mechanisms involved in foci growth. In the present study, the focal labeling index was markedly enhanced in all 3 strains as compared to surrounding normal tissue, clearly demonstrating the enhanced proliferation activity in hepatic foci. The focal labeling index was lower in C57 mice as compared with B6C3F1 and C3H mice. A similar straindependent difference in focal cell proliferation has previously been reported in N -ethyl-nitrosourea-treated C57 and C3H mice (14) . The labeling index was lower in the DEN PB-treated B6C3F1 mice relative to the DEN-initiated B6C3F1 mice; no such difference was observed in C3H mice. Collectively, these ndings correlated well with focal growth and size changes observed in the mouse strains between 5 and 9 months, supporting the crucial role of cell proliferation in regulating the growth of hepatic foci (12, 14) .
Apoptosis may act as a counterpart to cell proliferation, and modi cation of apoptosis may either stimulate or inhibit foci growth (10) . In the present study, the insuf cient number and size of foci prevented a reliable determination and a de nitive conclusion of focal apoptosis at 5 months in all 3 strains as well as at 9 months in C57 mice. However, the fact that no focal apoptotic bodies were found in foci at 5 months in all 3 strains as well as at 9 months in C57 mice despite the fact that more than 10,000 nuclei were counted indicates a low intrafocal apoptotic index in these groups at these time points relative to 9-month DEN-and DEN PB-treated B6C3F1 and C3H mice. At 9 months, DEN-and DEN PB-treated B6C3F1 mice had similar intrafocal apoptotic indices, indicating that PB did not affect apoptosis in DEN-induced foci in B6C3F1 mice. In C3H mice, however, the DEN PB treated group had an approximately 3-fold higher intrafocal apoptotic index than the DEN group. The relatively high apoptotic index in DEN PB-treated C3H mice was mainly due to the substantial number of apoptotic bodies detected in amphophilic and mixed foci. When these foci were excluded, no difference in intrafocal apoptosis was observed between DEN-and DEN + PB-treated C3H mice. The high apoptotic index observed in amphophlic and mixed foci are consistent with previous ndings in rats, perhaps indicating phenotypic diversity and instability (39) . Between 5 and 9 months, the conversion of foci to tumors was most ef cient in C3H mice followed by B6C3F1 mice and C57 mice. However, when 5-month foci were compared with 12-month masses, no strain difference were observed, suggesting that relatively early conversion of foci to tumors occurs in susceptible mouse strains. Conversion from foci to tumors represents the progressive stage of hepatocarcinogenesis by which additional genomic alterations are believed to take place, leading to additional mutations and eventually malignancy (26, 27) . The fact that differences in conversion was only notable when comparing 5-month foci with 9-month masses may suggest an association with focal growth, where increased cell growth may contribute to the earlier onset of conversion by increasing genomic instability or by selecting for more aggressive cells (34) . Difference in growth signals may exist among the strains, leading to an override of cell cycle checkpoints and de cient DNA repair in a time-dependent fashion among the mouse strains (12) . Further studies investigating the importance of checkpoint disruption and subsequent genomic instability in the different stages of mouse liver carcinogenesis are needed.
The present study demonstrates the important role of cell growth in hepatic foci and tumor development in comparatively resistant and susceptible mice. Although liver foci and mass incidence as well as mass multiplicity and number of foci were not changed over time, the size of DENinduced foci and macroscopic lesions was substantially increased over time. Results indicate that cell proliferation plays a major role in foci growth and that intrafocal apoptosis may act late in foci development by preventing growth and possibly also by promoting focal cell selection. Furthermore, our data suggest that extrafocal apoptosis may have an important role in foci growth by removing surrounding normal cells, thereby facilitating noninvasive expansion of foci. The results also demonstrate a remarkable difference among mice in the responsiveness to PB on the growth rate of DENinduced foci and macroscopic lesions. PB substantially decreased foci and tumor growth in B6C3F1 mice and decreased focal cell proliferation. However, no such effect was observed in C3H mice suggesting that C3H mice have endogenous pathways to block the inhibitory effects of PB on growth and cell proliferation. These data also demonstrate that the onset of conversion of foci to tumors appears to correlate with mouse susceptibility to hepatocarcinogesis. Whereas clonal growth differences undoubtedly plays an important role in mouse susceptibility to mouse hepatocarcinogenesis, additional stages of carcinogenesis appear to be important in mouse liver tumor susceptibility. Different sensitivity and resistant genes may act throughout multistage hepatocarcinogenesis, dictating the development of mouse liver tumors and strain susceptibility.
